secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verrica Pharmaceuticals Inc. (VRCA)
CIK:        0001660334
Form:       8-K
Filed at:   2024-11-04T23:59:59+00:00
Accession:  0001193125-24-250638
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verrica Q3 net product revenue negative $1.9M; CEO Ted White resigns, replaced by Dr. Rieger
--------------------------------------------------------------------------------

- Negative net product revenue of $1.9M in Q3 2024, including $1.7M provision for returns; no ex-factory sales.
- Net loss of $22.9M ($0.49 per share) vs $24.8M ($0.54) in Q3 2023; non-GAAP loss $20.2M.
- CEO Ted White resigns effective Nov 5; Dr. Jayson Rieger appointed President, CEO, and director.
- John Kirby appointed Interim CFO; company engaged Jefferies to advise on strengthening balance sheet.
- Restructuring cuts operating expenses ~50%; VP-315 Phase 2 shows 51% complete histologic clearance for BCC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1660334/000119312524250638/0001193125-24-250638-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1660334/000119312524250638/d907851d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-250638

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer